

1 **Running Title:** Evaluation of a surrogate SARS-CoV-2 neutralization test

2 **Title:** Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of
3 antibody in human, canine, cat and hamster sera.

4 **Ranawaka APM Perera^{1*}, Ronald Ko^{1*}, Owen TY Tsang², Christopher J Brackman³,**
5 **Esther M. W. To³, Hui-ling Yen,¹ Kathy Leung¹, Samuel MS Cheng¹, Kin Ho Chan¹, Karl**
6 **CK Chan¹, Ka-Chi Li¹, Linda Saif⁴, Vanessa R. Barrs⁵, Joseph T Wu¹, Thomas H. C. Sit³,**
7 **Leo LM Poon^{1,6}, Malik Peiris^{1,6} #.**

8 **Affiliations:**

9 1. School of Public Health, The University of Hong Kong, Hong Kong Special Administrative
10 Region, China.

11 2. Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong.

12 3. Agriculture, Fisheries and Conservation Department, Government of the Hong Kong Special
13 Administrative Region, China.

14 4. Food Animal Health Research Program, OARDC/The Ohio State University, 1680 Madison
15 Ave, Wooster, Oh 44691, USA

16 5. Jockey Club College of Veterinary Medicine & Life Sciences, City University of Hong Kong,
17 Kowloon Tong, Hong Kong SAR China.

18 6. HKU-Pasteur Research Pole, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
19 Hong Kong SAR, China.

20

21 **Keywords:** SARS coronavirus 2; COVID-19; serology, neutralization, sero-epidemiology,
22 human, animal

23 **# Correspondence to:** Malik Peiris, School of Public Health, The University of Hong Kong, No 7
24 Sassoon Rd, Pokfulam, Hong Kong Special Administrative Region, China.

25 **Abstract—word count 71**

26 Surrogate neutralization assays for SARS-CoV-2 that can be done without biosafety-
27 level-3 containment and across multiple species are desirable. We evaluate a recently developed
28 surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization
29 tests (PRNT90) in human, canine, cat and hamster sera and found excellent concordance
30 between the two assays. Using a panel of immune sera to other coronaviruses, we confirm the
31 lack of cross reactivity in sVNT and PRNT90 assays.

32

33 **Introduction—word count (1184)**

34 SARS-CoV-2 virus emerged in 2019 to cause a pandemic. It is important to detect antibody
35 responses in humans and animals to ascertain evidence of past infection with SARS-CoV-2.
36 Antibody assays that are transferable across species are desirable because SARS-CoV-2 infects
37 pets and other farmed animals (e.g. mink) [1,2,3] and for monitoring antibody responses in
38 experimental animal models [4]. ELISA assays to the virus spike receptor binding domain
39 (RBD) which has least cross-reactive epitopes with other coronaviruses, the whole spike protein
40 or nucleoprotein are widely used for detection of antibody in humans [5,6,7]. Virus
41 neutralization assays are used for confirming positive results but require handling live virus in
42 biosafety level 3 (BSL-3) containment or a pseudotyped virus.

43 ELISA testing for antibody in other animal species requires assays to be re-optimized with the
44 relevant species-specific anti-Ig-conjugate for detecting immunoglobulins of each species. For
45 some species relevant anti-Ig reagents may not be available. The currently available generic
46 alternative has been to use virus neutralization tests which usually involves handling live virus in
47 BSL-3 containment. A “surrogate” virus neutralization test (sVNT) that can be done in BSL-2
48 containment has recently been reported [8]. It is an assay that relies on competitive inhibition of
49 the interaction of ACE-2 receptor coated on an ELISA plate with horse radish peroxidase
50 labelled virus spike receptor binding domain. We used a panel of sera from patients or animals
51 with RT-PCR confirmed SARS-CoV-2 infection and corresponding controls to evaluate this
52 sVNT assay in comparison to the “gold-standard” PRNT90 test.

53 **Materials and Methods:**

54 Sera: Sera (n=43) from SARS-CoV-2 RT-PCR confirmed patients and negative controls (n=42)
55 collected from blood donors in 2017 were used [6]. Dogs (n=4) and a cat with RT-PCR
56 confirmed SARS-CoV-2 were included in the study (4). Control dog sera were obtained from a
57 study of canine influenza in 2017 [9] and sera from cats submitted for routine veterinary
58 diagnostic testing in 2020 were used as controls. Hamster sera from experimentally infected
59 hamsters and controls were from a previous study [4].

60 Coronavirus immune sera: Immune sera specific for alphacoronaviruses (porcine respiratory
61 coronavirus, feline infectious peritonitis virus, canine coronavirus and porcine transmissible
62 gastroenteritis virus), betacoronaviruses (SARS-coronavirus) and gamma-coronavirus
63 (infectious bronchitis virus) were obtained from BEI Resources (animal CoV reagents supplied
64 to BEI by Dr Linda Saif (<http://www.beiresources.org/About/BEIResources.aspx>) or generated
65 by Dr Linda Saif (Table 2). Dr Stanley Perlman provided mouse serum to mouse hepatitis virus
66 (strains A59 and JHM) (Table 1). The homologous antibody titres to the immunising virus were
67 also provided by Dr Linda Saif or Dr Stanley Perlman (Table 2).

68 Serological tests: The SARS-CoV-2 surrogate virus neutralization test kits were obtained from
69 GeneScript USA, Inc, New Jersey, and the test carried out according to the manufacturer's
70 instructions. The test sera (60uL), positive or negative controls were diluted at 1:10 and mixed
71 with an equal volume of horse radish peroxidase (HRP) conjugated to SARS-CoV-2 spike
72 receptor binding domain (RBD) and incubated for 30 minutes at 37°C. Then, 100 µL each mix
73 was added to the wells on the microtiter plate coated with ACE-2 receptor, the plate was sealed
74 and incubated at 37°C for 15 minutes. The plates were then washed with wash-solution, tapped
75 dry and 100 µL of 3,3',5,5'-Tetramethylbenzidine (TMB) solution was added to each well and
76 incubated in the dark at room temperature for 15 minutes. The reaction was stopped by addition
77 of 50µL of Stop Solution to each well and the absorbance read at 450 nm in an ELISA reader.
78 Assuming the positive and negative controls gave the recommended OD₄₅₀ values, the %
79 inhibition of each serum was calculated as (1- OD value of the sample / OD value of the negative
80 control) x100. An inhibition of ≥20% is regarded as a positive result while that <20% is negative
81 [8].

82 SARS-CoV-2 90% plaque reduction neutralization titer was determined as previously described
83 [6].

84 **Ethical statement: Ethical statement:** Collection of serum from patients with COVID-19 and
85 healthy blood donor sera in 2017 was approved by the Research Ethics Committee of the
86 Kowloon West Cluster reference No. KW/EX-20-039 (144-27) of the Hospital Authority of
87 Hong Kong and the Institutional Review Board of The Hong Kong University and the Hong
88 Kong Island West Cluster of Hospitals (IRB reference number UW16-254), respectively. Canine
89 sera were residual sera from sera collected as part of routine clinical care and the Committee on
90 the Use of Live Animals in Teaching and Research (CULATR) has waived animal ethics
91 approval. Cat sera were residual sera collected routine diagnosis. The experimental study on
92 hamsters was approved by the Committee on the Use of Live Animals in Teaching and Research,
93 The University of Hong Kong (CULATR # 5323-20).

94

95 **Results and Discussion:**

96 Human (n=85), dog (n=44), cat (n=20) and hamster (n=5) sera from SARS-CoV-2 infected or
97 controls, with known plaque reduction neutralization titres results, were tested in the sVNT
98 assay. The concordance between the sVNT test and PRNT90 test was 100%, with all 47
99 PRNT90 positive sera also being positive in the sVNT assay while all 107 PRNT90 negative sera
100 were negative in the sVNT (Table 1). Three of 4 sera collected from two RT-PCR positive dogs
101 were positive in both sVNT and PRNT90 assays, the negative serum being an early serum
102 collected from a dog which subsequently seroconverted by both assays. All 37 human sera from
103 RT-PCR confirmed human patients obtained 10 or more days after onset of illness were positive
104 in both assays whereas 3 of 6 sera collected prior to day 10 after illness onset were sero-negative
105 in both assays. The sVNT assay is not meant to be quantitative. However, there was a semi-
106 quantitative relationship between the % inhibition in the sVNT assay and PRNT90 titres
107 (Figure).

108 We investigated cross reactivity of immune sera to a range of alpha, beta and gamma
109 coronaviruses in the sVNT and PRNT90 assays including antisera to feline infectious peritonitis

110 virus, canine coronavirus, mouse hepatitis virus and SARS-CoV (Table 2). Two human SARS-
111 CoV convalescent plasma samples were also included in this assessment. Cross reactivity in the
112 sVNT assay was only detected with SARS convalescent human plasma (homologous PRNT90
113 titers of 1:160 and 1:320) and with a Guinea pig immune sera to SARS-CoV with a homologous
114 neutralization titer of 1:2,560. Cross reactivity in the SARS-CoV-2 PRNT90 test was only
115 observed with the high titre hyperimmune rabbit sera to SARS-CoV (homologous antibody titer
116 1:640).

117 We found excellent concordance between the sVNT and the “gold-standard” PRNT90 assays for
118 SARS-CoV-2 antibody detection in humans, dogs, cat and hamster sera. It is likely that the
119 sVNT assay can be used to detect SARS-CoV-2 antibody in any species in a highly specific and
120 convenient manner. This assay would be of great utility as a species independent assay for
121 primary testing for SARS-CoV antibodies in humans of animals or for independent confirmation
122 of sera giving positive ELISA antibody results. While there was an overall correlation between
123 PRNT90 titers and % inhibition in the sVNT assay, antibody quantitation of sVNT remains a
124 challenge. We did not compare its performance with pseudo-particle neutralization assays for
125 antibody. The sVNT test has the advantage of technical simplicity, speed, and not requiring cell
126 culture facilities and BSL-3 containment.

127 **Acknowledgments**

128 We acknowledge research funding from the Health and Medical Research Fund, the Food
129 and Health Bureau, The Government of Hong Kong Special Administration Region. We thank
130 Dr Stanley Perlmann for the mouse hepatitis virus immune sera and relevant serological data.
131 We thank Linfa Wang at Duke-NUS and GenScript for advice on the sVNT.

132 **Conflict of interest**

133 None declared.

134

135 **References**

- 136 1. Sit THC, Brackman CJ, Ip SM, Tam KWS, Law PYT, To EMW, Yu V.Y.T, Sims L.D, Tsang
137 D.N.C, Chu D.K.W, Perera R.A.P.M, Poon L.L.M, Peiris M. Infection of dogs with SARS-CoV-
138 2 [published online ahead of print, 2020 May 14]. *Nature*. 2020;10.1038/s41586-020-2334-5.
139 doi:10.1038/s41586-020-2334-5
- 140 2. Newman A, Smith D, Ghai RR, Wallace RM, Torchetti MK, Loiacono C, Murrell LS,
141 Carpenter A, Moroff S, Rooney JA, Behravesh CB. First Reported Cases of SARS-CoV-2
142 Infection in Companion Animals — New York, March–April 2020. *MMWR Morb Mortal Wkly*
143 *Rep* 2020;69:710–713. [http://dx.doi.org/10.15585/mmwr.mm6923e3external icon](http://dx.doi.org/10.15585/mmwr.mm6923e3external%20icon).
- 144 3. Oreshkova N, Molenaar RJ, Vreman S, Harders F, Oude Munnink BB, Hakze-van der Honing
145 RW, Gerhards N, Tolsma P, Bouwstra R, Sikkema RS, Tacken MGJ, Rooij MMT, Weesendorp
146 E, Engelsma MY, Brusckhe CJM, Smit LAM, Koopmans M, Poel WHM, Stegeman A,
147 Stegeman A. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020.
148 *Euro Surveill*. 2020;25(23):10.2807/1560-7917.ES.2020.25.23.2001005. doi:10.2807/1560-
149 7917.ES.2020.25.23.2001005
- 150 4. Sia SF, Yan LM, Chin AWH, Fung K, Choy KT, Wong AYL, Kaewpreedee P, Perera RAPM,
151 Poon LLM, Nicholls JM, Peiris M, Yen HL. Pathogenesis and transmission of SARS-CoV-2 in
152 golden hamsters [published online ahead of print, 2020 May 14]. *Nature*. 2020;10.1038/s41586-
153 020-2342-5. doi:10.1038/s41586-020-2342-5
- 154 5. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K,
155 Arunkumar GA, Jurczynszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin
156 L, Fierer DS, Lugo LA, Kojic EM, Stoeber J, Liu STH, Cunningham-Rundles C, Felgner PL,
157 Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM,
158 Simon V, Krammer F. A serological assay to detect SARS-CoV-2 seroconversion in humans
159 [published online ahead of print, 2020 May 12]. *Nat Med*. 2020;10.1038/s41591-020-0913-5.
160 doi:10.1038/s41591-020-0913-5.
- 161 6. Perera RAPM, Mok CK, Tsang OT, Lv H, Ko RLW, Wu NC, Yuan M, Leung WS, Chan
162 JMC, Chik TSH, Choi CYC, Leung K, Chan KO, Chan KCK, Li KC, Wu JT, Wilson IA, Monto

163 AS, Poon LLM, Peiris M. Serological assays for severe acute respiratory syndrome coronavirus
164 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):2000421. doi:10.2807/1560-
165 7917.ES.2020.25.16.2000421

166 7. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,
167 Sikkema RS, Bruin E, Chandler FD, Yazdanpanah Y, Hingrat QL, Descamps D, Houhou-Fidouh
168 N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. Severe Acute
169 Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease
170 Patients. Emerg Infect Dis. 2020;26(7):1478-1488. doi:10.3201/eid2607.200841.

171 8. Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C, Hu Z, Chen VCW, Young BE, Sia WR,
172 Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. A SARS-CoV-2 surrogate virus
173 neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-
174 protein interaction. 2020; <https://www.researchsquare.com/article/rs-24574/v1>

175 9. Su W, Kinoshita R, Gray J, Ji Y, Yu D, Peiris JSM, Yen HL. Seroprevalence of dogs in Hong
176 Kong to human and canine influenza viruses. Vet Rec Open. 2019;6(1):e000327. Published 2019
177 Apr 11. doi:10.1136/vetreco-2018-000327

178

179 **Figure Legend:**

180 **Figure: Correlation between 90% plaque reduction neutralization test (PRNT 90) titer and**
181 **the percent inhibition in the surrogate virus neutralization test (sVNT).** We fit a linear-log
182 regression model between the percent inhibition in the sVNT assay and log-transformed
183 PRNT90 titration titers. The orange line showed the estimated percent of inhibition and the
184 orange shades showed the 95% confidence interval. Blue dots showed the control samples. Black
185 triangles showed samples from confirmed COVID-19 cases obtained less than 10 days since
186 symptom onset and red diamonds showed samples from confirmed cases obtained at least 10
187 days after symptom onset.

188

189

Table 1: Performance characteristics of the surrogate virus neutralization (sVN) test in comparison with 90% plaque reduction neutralization test

	sVNT pos / PRNT90 pos PRNT titers and sVN % inhibition	sVNT neg / PRNT90 neg	sVNT / PRNT90 discrepant	Total
SARS-CoV-2 infected dogs	3 (PRNT titres 40, 80, 160 sVNT %inhibition 33%, 66%, 78%)	1 (acute serum, later seroconverted)	0	4
Control dogs	0	40	0	40
SARS-CoV-2 infected cats	1 (PRNT titer320; sVNT % inhibition 83%)	0	0	1
Control cats	0	19	0	19
SARS-CoV-2 infected hamsters	3 (PRNT titers 320, 640, 640; sVNT % inhibition 83%; 83%; 83%)	0	0	3
Control hamsters	0	2	0	2
SARS-CoV-2 infected human sera				
<10 days after illness onset	3#	3	0	6
≥10 days after illness onset	37#	0	0	37
Sera from humans collected in 2017	0	42	0	42
Total	47	107	0	154

Correlation between PRNT titers and sVNT % inhibition is shown in figure.

Table 2: SARS-CoV-2-CoV surrogate virus neutralization (sVN) and 90% plaque neutralization (PRNT90) cross-reactivity with immune sera to other coronaviruses.

Genus	Antiserum	Homologous Ab titre by ELISA or virus neutralization (VN) as indicated	PRNT90 titer	sVNT % inhibition	sVN result
Alphacoronavirus	Gnotobiotic pig antiserum to porcine respiratory coronavirus – NR-460	ELISA 1:1,200 ^a	<1:10	8.39%	Negative
	Guinea pig antiserum to feline infectious peritonitis virus – NR-2518	ELISA 1:2,000 ^a	<1:10	13.17	Negative
	Guinea pig antiserum to canine coronavirus – NR-2727	ELISA 1:4,094 ^b	<10	17.20	Negative
	Gnotobiotic pig antiserum to porcine transmissible gastroenteritis virus – NR-458	ELISA 1:1,400 ^a	<1:10	12.76	Negative
Betacoronavirus	Guinea pig anti-SARS-CoV – NR-10361	VN 1:2,560 ^b	<1:10	81.14	Positive
	Rabbit antiserum for SARS-CoV S protein (Control) – NRC-769	VN <1:10	<1:10	13.68	Negative
	Rabbit antiserum for SARS-CoV S protein (low titre) – NRC-770	VN 1:80	<1:10	78.44	Positive
	Rabbit antiserum for SARS-CoV S protein (medium titre) – NRC-771	VN 1:160	<1:10	75.30	Positive
	Rabbit antiserum for SARS-CoV S protein (high titre) – NRC-772	VN 1:640	1:10	79.59	Positive
	Human SARS convalescent plasma (E222P)	VN 1:160 ^d	<1:10	28.39	Positive
	Human SARS convalescent plasma (E229P)	VN 1:320 ^d	<1:10	36.39	Positive
	Mouse hepatitis virus (A59 strain) infected mouse	VN 1:1000 ^c	<1:10	14.76	Negative
	Hyper-immunised mouse serum to mouse hepatitis virus (JHM strain)	VN 1,1778 ^c	<10	9.73	Negative
Gammacoronavirus	Guinea pig antiserum to infectious bronchitis virus – NR-2515	ELISA 1:50,000 ^a	<1:10	15.16	Negative

Abbreviations. Ab: Antibody; ELISA: enzyme-linked immunosorbent assay; PRNT90: 90% plaque reduction neutralization antibody; SARS-CoV: severe acute respiratory syndrome coronavirus.

sVNT inhibition of $\geq 20\%$ is regarded as positive and $< 20\%$ as negative.

All homologous antibody titres are ELISA titres except for antibody titers to SARS-CoV and mouse hepatitis virus which are neutralizing antibody titers.

Homologous antibody titres: ^aData obtained from BEI-Resources. ^bData obtained from Linda Saif. ^cData from Dr Stanley Perlman; ^dNeutralizing antibody titers from our laboratory

